Rituximab for MS may safely control disease in children, teens
Treatment with rituximab, an approved CD20 inhibitor that’s sometimes used off-label for multiple sclerosis (MS), was found to adequately control the neurodegenerative disease in patients diagnosed during childhood or adolescence, a new study showed. The therapy, given byĀ infusion into the bloodstream, was generally safe and significantly reduced…